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Spheres of Influence
What's Good for the Gander May Not Be Good for
the Goose
Statistically speaking, a woman is not as
healthy as her male counterpart. She experi-
ences more chronic health problems, more
unique health problems, and reacts differ-
ently, even to a garden variety of ailments,
over the course ofher lifetime. Yet ask any
reputable scientist to identify the best ways
to determine causes, prevention, and treat-
ment of illness in particular regard to
women, and the likely response is a ques-
tion mark. Women have traditionally
borne the health consequences of being
underrepresented or banned from clinical
research simply on the basis ofgender, but
the tide is about to turn.
As Palma E. Formica, a member ofthe
American Medical Association's Board of
Trustees, recently observed, women are
"different biological entities from men,
with different hormones, patterns of dis-
ease, health, and responses to treatment."
Researchers and physicians alike are begin-
ning to notice. Progress is being made in
closing the gap in so-called gender bias in
clinical trials, with sweeping reforms being
made by the legal, political, and medical
systems. New federal studies, regulations,
and ethical guidelines are in the works to
encourage the use of females as research
subjects in order for scientists to better
understand and more effectively treat
women.
According to an unpublished report by
the NIEHS, women are more likely to
develop or experience worse effects of a
variety of environmentally linked health
problems. The NIEHS study indicated
that a woman's greater percentage of body
fat, use of oral contraceptives and estrogen
replacement therapy, and exposure to heavy
metals and other toxins may raise her odds
for cancer, endometriosis, fibroids, osteo-
porosis, and cardiovascular disease. Yet
prompted by concerns that experimental
procedures or treatments pose unacceptable
risks for women of childbearing age, trials
for cardiovascular disease, cancer, AIDS,
and many other diseases have been con-
ducted only on men or postmenopausal
women or not separately measured, leaving
fertile women without clinically proven safe
and effective medical treatments.
Lack ofhard evidence about the impact
oftoo few or no female subjects in research
has compelled researchers to play guessing
games. "Because women have often been
excluded. . . the medical community has
had to assume, sometimes incorrectly, that
what is good for men is also good for
women," said former National Institutes of
Health Director Bernadine Healy. "It's a
case of wrong-headed expectations leading
sometimes to the wrong treatment, deliv-
ered too late."
Healy's call to reconcile the imbalance
between research and practice is showcased
by the largest community-based clinical
intervention and prevention trial ever con-
ducted in the United States. At a press
conference in March, Healy named 16
Van-guard centers to carry out clinical
studies of the leading causes of death and
disability in women, with 4 centers mainly
targeting minority participants. Twenty-
nine more centers will be announced by
mid-1994.
More than 160,000 women, ages 50 to
79, will take part in the Women's Health
Initiative, a $625-million, 15-year study of
the causes and prevention of heart disease,
cancer, and osteoporosis-the major causes
ofdeath and disability in women. Accord-
ing to Healy, by September each center will
enroll about 3500 study participants be-
yond childbearing age in a series ofclinical
trials or observational studies. The objec-
tive is to test the effects of a low-fat diet,
dietary supplements, exercise, hormone
therapy, and smoking cessation in prevent-
ing colorectal and breast cancer and hip
fractures.
On the environmental front, a series of
upcoming workshops and studies on wom-
en and cancers caused by workplace expo-
sures are on a growing roster of govern-
ment-funded projects. "The environment
affects us and we affect the environment, so
it's a very symbiotic relationship . . . we as
human beings must understand the interac-
tion," said Judith H. LaRosa, deputy direc-
tor of the Office of Research on Women's
Health at the NIH, which is co-sponsoring
a study with NIEHS to determine the epi-
demiology oflead, diet, and blood pressure,
amongother projects.
Researchers say females are usually
excluded from animal studies unless their
physiology is studied, while female clinical
trial participants are not probed to see how
orwhy they reactvariably largely because of
their hormonal variations, need for contra-
ception, contraception counseling, and
potential for pregnancy. "This means phar-
maceutical companies can market drugs
with no information about their reproduc-
tive impact and. . .large-scale clinical trials
with female subjects are never conducted,"
said Vanessa Merton, associate dean for
Clinical Education and professor at Pace
University School ofLaw.
Until now, the Food and Drug Admin-
istration's guidelines kept fertile women out
ofany clinical trial before its final stages and
then only after generating animal data on a
treatment's reproductive and teratogenic
effects. This spring the FDA gave the green
light for women of childbearing age to
enroll in phase 1, 2, and large-scale phase 3
trials on new drug applications. "We are
also requiring gender analysis which we had
asked for but discovered was not being done
as frequently as we would have liked," said
Ruth Merkatz, special assistant on women's
health issues to FDA Commissioner David
Kessler. Gender analysis refers to monitor-
ing and recording differences in clinical data
between men and women.
Merkatz indicated that FDA plans to
explore when and how pregnant women
could participate in clinical trials, but gave
no timetable or conditions. She said more
active surveillance after marketing is crucial,
as physicians now prescribe medications to
an expectant mother with no specified data.
"They have been flying by the seat of their
pants-not knowing whether a dosage works
or how because her hormonal milieu is so
different," Merkatz said, pointing to FDA's
directive last year against acetylcholin-
esterase inhibitors for pregnant women with
high blood pressure after a series of babies
died in utero. The Department of Health
and Human Services' regulations also
restrict the use ofpregnant women to clini-
cal trials where treatment is therapeutic with
minimal risk to the fetus.
Some legal scholars argue such policies
are discriminatory and unconstitutional.
"After fully being informed of the risks, [a
woman] is told she cannot be trusted to
decide whether to participate in a protocol,
while no restriction is placed on men whose
offspring may be at equal risk," Merton
said.
Heightened interest in women's health
needs comes four decades after diethylstilbe-
strol (DES), a synthetic estrogen, was linked
to various health problems. Researchers
found that women who took the drug to
prevent threatened miscarriages were more
prone to breast cancer, and their daughters
are now vulnerable to vaginal cancer. It is
more than three decades since thalidomide,
a sedative taken by expectant mothers,
resulted in severelydeformed babies.
Long cited by research sponsors as
grounds to exclude women from research
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studies, many critics now dub such catastro-
phies "red herrings." "Those tragedies were
caused not by research studies but lack of
testing and safeguards in postmarketing sur-
veillance into the drugs' potential for harm-
ing pregnant women," says a congressional
staffer.
A 1991 NIH memorandum said under-
representation ofwomen in clinical studies
has caused significant gaps in medical
knowledge. "Without adequate representa-
tion of women in study populations, we
cannot truly know whether we are most
effectively diagnosing, treating, and prevent-
ing illness in ourwomen patients," saidJean
Hamilton, a member of the American
Medical Women's Association, who spoke
before the NIH panel on women's recruit-
ment and retention in research studies.
A 1992 General Accounting Office
(GAO) study criticized the NIH's pace in
honoring its commitment to recruit women
as research subjects.
The report criticized the NIH for scanty
representations of women and minority
subjects in federally funded, industry-spon-
sored research trials submitted as evidence
for all drugs approved by the FDA since
1988. The landmark study coincided with
a flurry of legislation and regulations that
would mandate equal access to clinical tri-
als.
In response to criticism from the GAO
and Congress, the NIH buoyed its policy
on including women in study populations
and developed an action plan for women's
health. The Public Health Service estab-
lished the Office of Women's Health.
Meanwhile, in 1990 the Office ofResearch
on Women's Health (ORWH) was set
within the Office of the Director of the
National Institutes ofHealth. This office is
charged with coordinating research related
to diseases, disorders, and conditions that
affect women, assuring that women are well
represented in research studies, and promot-
ing the recruitment, retention, reentry, and
advancement of women in biomedical
careers.
The latest version of the Women's
Health Equity Act, which is part of the
NIH reauthorization bill, is in conference.
The bill codifies the ORWH as part ofthe
NIH statute, requires the inclusion of
women and minorities in clinical trials, and
expands research on specific women's health
needs. According to a congressional staffer,
some $470 million is authorized for the act,
which is expected to be signed into law by
President Clinton this spring.
Meanwhile, headway is being made to
audit NIH grants by the Congressional
Women's Caucus, an assembly of female
members ofCongress that is trying to deter-
mine how many grants received a waiver to
exclude women from research studies and
how many grants were for studies of one
gender. "No one thought a couple oflaws
would be a magic wand," said Congress-
woman Patricia Schroeder (D-Colorado), a
member ofthe caucus. "We're making sure
women figure into new research proposals
coming up so there is solid information
based on solid research."
Inclusion of women in research trials
raises dozens of thorny questions, some of
which were considered recently at a work-
shop by the National Academy ofScience's
Institute of Medicine Committee on Legal
and Ethical Issues Relating to the Inclusion
ofWomen in Clinical Studies. Testifying
before the committee, R. Alta Charo, assis-
tant professor at the University ofWiscon-
sin Schools of Law and Medicine, argued
that excluding women from government-
funded research and potentially lifesaving
treatments deprives a woman ofher consti-
tutional right to life and liberty and guaran-
tees of equal protection under the law.
Moreover, Charo contends that legally bar-
ring pregnant women from clinical trials
seems to "elevate concerns for fetal well-
being over concerns for maternal and female
well-being."
Fetal well-being is indeed a concern and
raises another facet of the issue, which was
addressed by Michelle Oberman, a profes-
sor at DePaul University College ofLaw in
Chicago, in testimony before an NIH panel
on women's recruitment and retention in
clinical trials: "The much greater perceived
cost of including fertile women in clinical
studies relates to the sponsors' fear that a
woman will conceive while in the study,
will choose to carry the pregnancy to term,
and will give birth to a child with disabili-
ties."
What is good for the proverbial goose
may not be good for the gosling. "Unlike
the adult subject in a clinical trial who
knowingly consents to risk and thereby
waives the right to sue for injuries, a child
who is harmed while in utero through a
clinical study may well have a cause of
action against those who caused the in-
jury," added Oberman, speaking on behalf
of the Chicago Bar Association Alliance
for Women, an advocacy group seeking
legal reforms.
Clearly, there are significant disincen-
tives to including fertile women in clinical
studies, particularly in terms of increased
concerns about costly lawsuits and medical
treatment for injured subjects and their off-
spring. But because fertile women also need
medical treatment there are costs of exclud-
ing them from trials that can show once and
for all that the treatments they opt for are
safe and effective. This is the dilemma that
until now has limited or even precluded
women from being included in clinical trials.
Researchers historically have used many
justifications to exclude women from
research studies. They argue that women are
harder to recruit and retain; that male-only
data are more homogenous and thus more
useful; that inclusion of women is unduly
costly; that government regulations require
theirexclusion; and that the threat to fetuses
creates a legal and moral imperative to
exclude all potentially pregnant women.
Many participants at the Institute of Med-
icine meeting, such as Debra A. DeBruin, a
professor in the Department of Philosophy
at the University of Illinois at Chicago,
believe that these criteria are flawed, unjust,
and likely to be overturned. In regard to
cost, DeBruin said that it is unethical to dis-
perse resources on the basis ofsex. "Surely,
no one. . .would be willing to manage the
costs ofeducation by excluding children of
color from our educational system," she
said. "Likewise we must conclude that con-
siderations of cost cannot justify excluding
women from dinical studies."
Should legal and political roadblocks to
inclusion ofwomen in clinical trials be over-
come, however, advocates believe the system
must still work to accommodate and en-
courage female subjects deterred both by
logistics such as child care, transportation,
and cost (many third-party payers will not
cover medical costs for clinical trials even
when the standard treatment costs as much
or more) as well as basic concerns about
safety and credibility.
Despite the obstacles, evidence is
mounting that given the chance, women
want to participate. In one major nation-
wide clinical trial, many more of the 800
initial participants remained to complete the
trial than sponsors expected. Speaking for
the Society for the Advancement of
Women's Health Research in Washington,
DC, Maria Bustillo said the Postmeno-
pausal Estrogen Progestin Interventions trial
showed that self-interest and altruism are
prime motivators. "Women expressed inter-
est in knowing more about their own health
and... .in increasing knowledge about hor-
mone replacement to benefit future genera-
tions."
For women, inclusion in clinical re-
search trials means acquiring vital knowl-
edge about their unique illnesses, physiolo-
gies, and responses to treatment in the hope
that with such knowledge comes the power
to ensure that they, like their male counter-
parts, receive the benefits of medical and
scientific research. These benefits, due to
women's unique capacity to bear children,
maythen be passed to societyas awhole.
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